Clinname	Result
NCT01877187	No publish
NCT01877187	No publish
NCT02557503	No publish
NCT02753881	No publish
NCT01164202	No publish
NCT00128596	No publish
NCT00949182	No publish
NCT02013830	No publish
NCT00867321	No publish
NCT01324076	No publish
NCT03092895	No publish
NCT00605722	No publish
NCT00087282	No publish
NCT00717756	Safran H, Charpentier KP, Kaubisch A, Mantripragada K, Dubel G, Perez K, Faricy-Anderson K, Miner T, Eng Y, Victor J, Plette A, Espat J, Bakalarski P, Wingate P, Berz D, Luppe D, Martel D, Rosati K, Aparo S. Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study. Am J Clin Oncol. 2015 Feb;38(1):1-4. doi: 10.1097/COC.0b013e3182868c66.
NCT00006006	Schwartz JD, Sung M, Schwartz M, Lehrer D, Mandeli J, Liebes L, Goldenberg A, Volm M. Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression. Oncologist. 2005 Oct;10(9):718-27.
NCT02069145	No publish
NCT00077142	Higginbotham KB, Lozano R, Brown T, Patt YZ, Arima T, Abbruzzese JL, Thomas MB. A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma. J Cancer Res Clin Oncol. 2008 Dec;134(12):1325-35. doi: 10.1007/s00432-008-0406-2. Epub 2008 May 27.
NCT02321202	No publish
NCT00003912	Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. doi: 10.1056/NEJMoa0810613.
NCT00003044	No publish
NCT02716012	No publish
NCT00191412	No publish
NCT01182272	No publish
NCT01075113	No publish
NCT01005199	No publish
NCT02292173	No publish
NCT00881751	No publish
NCT03143270	No publish
NCT00875615	No publish
NCT01011010	No publish
NCT01075555	No publish
NCT00410956	Kemeny NE, Schwartz L, G nen M, Yopp A, Gultekin D, D'Angelica MI, Fong Y, Haviland D, Gewirtz AN, Allen P, Jarnagin WR. Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? Oncology. 2011;80(3-4):153-9. doi: 10.1159/000324704. Epub 2011 Jun 14.
NCT00941967	No publish
NCT00003424	No publish
NCT00514228	Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kov��cs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.
NCT00483405	Sanoff HK, Bernard S, Goldberg RM, Morse MA, Garcia R, Woods L, Moore DT, O'Neil BH. Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab for Advanced Hepatocellular Carcinoma. Gastrointest Cancer Res. 2011 May;4(3):78-83.
NCT00467194	No publish
NCT00004248	No publish
NCT00054262	No publish
NCT00257426	No publish
NCT00335829	No publish
NCT00041275	Chow PK, Machin D, Chen Y, Zhang X, Win KM, Hoang HH, Nguyen BD, Jin MY, Lobo R, Findlay M, Lim CH, Tan SB, Gandhi M, Soo KC; Asia-Pacific Hepatocellular Carcinoma Trials Group. Randomised double-blind trial of megestrol acetate vs placebo in treatment-naive advanced hepatocellular carcinoma. Br J Cancer. 2011 Sep 27;105(7):945-52. doi: 10.1038/bjc.2011.333. Epub 2011 Aug 23.
NCT00030082	No publish
NCT00095992	Knox JJ, Gill S, Synold TW, Biagi JJ, Major P, Feld R, Cripps C, Wainman N, Eisenhauer E, Seymour L. A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). Invest New Drugs. 2008 Jun;26(3):265-72. doi: 10.1007/s10637-007-9103-2. Epub 2008 Jan 15.
NCT00058487	Zhu AX, Fuchs CS, Clark JW, Muzikansky A, Taylor K, Sheehan S, Tam K, Yung E, Kulke MH, Ryan DP. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. Oncologist. 2005 Jun-Jul;10(6):392-8.
NCT00825955	No publish
NCT00006010	Alberts SR, Reid JM, Morlan BW, Farr GH Jr, Camoriano JK, Johnson DB, Enger JR, Seay TE, Kim GP. Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trial. Am J Clin Oncol. 2012 Oct;35(5):418-23.
NCT00004108	No publish
NCT00012324	Gish RG, Porta C, Lazar L, Ruff P, Feld R, Croitoru A, Feun L, Jeziorski K, Leighton J, Gallo J, Kennealey GT. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol. 2007 Jul 20;25(21):3069-75.
NCT00576199	No publish
NCT00471484	Ang MK, Poon D, Foo KF, Chung YF, Chow P, Wan WK, Thng CH, Ooi L. A new chemoimmunotherapy regimen (OXAFI) for advanced hepatocellular carcinoma. Hematol Oncol Stem Cell Ther. 2008 Jul-Sep;1(3):159-65.
NCT00079027	No publish
NCT00276705	No publish
NCT00047229	Knox JJ, Chen XE, Feld R, Nematollahi M, Cheiken R, Pond G, Zwiebel JA, Gill S, Moore M. A phase I-II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798). Invest New Drugs. 2008 Apr;26(2):193-4. Epub 2007 Dec 4.
NCT03037437	No publish
NCT02181075	No publish
NCT00997022	No publish
NCT02829359	No publish
NCT01754987	No publish
NCT03397654	No publish
NCT01264705	No publish
NCT00706576	No publish
NCT00006198	No publish
NCT00813293	No publish
NCT00374660	No publish
NCT00057980	No publish
NCT01395030	No publish
NCT00652132	No publish
NCT00006016	No publish
NCT01236690	No publish
NCT00365391	No publish
NCT02862587	No publish
NCT00052364	No publish
NCT00003907	No publish
NCT01497444	No publish
NCT00093444	No publish
NCT00287976	No publish
NCT01932385	No publish
NCT00077389	No publish
NCT02649153	You XM, Mo XS, Ma L, Zhong JH, Qin HG, Lu Z, Xiang BD, Wu FX, Zhao XH, Tang J, Pang YH, Chen J, Li LQ. Randomized Clinical Trial Comparing Efficacy of Simo Decoction and Acupuncture or Chewing Gum Alone on Postoperative Ileus in Patients With Hepatocellular Carcinoma After Hepatectomy. Medicine (Baltimore). 2015 Nov;94(45):e1968. doi: 10.1097/MD.0000000000001968.
NCT03164382	No publish
NCT00242502	No publish
NCT02471313	No publish
NCT00861783	Jimeno A, Chan A, Cusatis G, Zhang X, Wheelhouse J, Solomon A, Chan F, Zhao M, Cosenza SC, Ramana Reddy MV, Rudek MA, Kulesza P, Donehower RC, Reddy EP, Hidalgo M. Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay. Oncogene. 2009 Jan 29;28(4):610-8. doi: 10.1038/onc.2008.424. Epub 2008 Nov 24.
NCT03184493	No publish
NCT00282100	No publish
NCT02646137	No publish
NCT03215355	No publish
NCT01042041	No publish
NCT02029157	No publish
NCT00247676	No publish
NCT00001587	No publish
NCT00003994	No publish
NCT01180959	No publish
NCT00250822	No publish
NCT01356628	No publish
NCT00321594	No publish
NCT01545804	No publish
NCT00238394	No publish
NCT00513461	No publish
NCT02174549	No publish
NCT00370513	No publish
NCT00728078	Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ, Lau WY. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006 Mar;243(3):321-8.
NCT00845689	No publish
NCT02702323	No publish
NCT01033240	No publish
NCT00507585	No publish
NCT01624285	No publish
NCT00019786	Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, Steinberg SM, Liewehr DJ, Kleiner DE, Alexander HR. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003 Dec 15;21(24):4560-7.
NCT00361309	No publish
NCT03352349	No publish
NCT00604721	No publish
NCT02509507	No publish
NCT00083226	No publish
NCT00077441	No publish
NCT00775073	No publish
NCT00001576	No publish
NCT01375569	No publish
NCT00071994	No publish
NCT00047346	No publish
NCT03259867	No publish
NCT00076609	No publish
NCT02695628	No publish
NCT03059238	Lv N, Kong Y, Mu L, Pan T, Xie Q, Zhao M. Effect of perioperative parecoxib sodium on postoperative pain control for transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma: a prospective randomized trial. Eur Radiol. 2016 Oct;26(10):3492-9. doi: 10.1007/s00330-016-4207-8. Epub 2016 Jan 22.
NCT00980239	No publish
NCT02744248	No publish
NCT00555334	No publish
NCT02940496	No publish
NCT00829413	No publish
NCT00788697	No publish
NCT00587067	No publish
NCT00844168	No publish
NCT02911961	No publish
NCT01853618	No publish
NCT03151213	No publish
NCT02202564	No publish
NCT01008566	No publish
NCT03211416	No publish
NCT00542048	No publish
NCT00081848	No publish
NCT03533582	No publish
NCT01775501	No publish
NCT00960557	No publish
NCT01782573	No publish
NCT00183885	No publish
NCT00732836	No publish
NCT01642186	No publish
NCT01306058	No publish
NCT01666756	No publish
NCT02191878	No publish
NCT00149396	No publish
NCT00304135	Phelip JM, Vendrely V, Rostain F, Subtil F, Jouve JL, Gasmi M, Michel P, Le Malicot K, Smith D, Seitz JF, Fauchart JP, Martin P, Bennouna J, Morin T, Bonnet I, Maingon P, Lepage C, Chauffert B. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: F��d��ration Francophone de Canc��rologie Digestive 9902 phase II randomised study. Eur J Cancer. 2014 Nov;50(17):2975-82. doi: 10.1016/j.ejca.2014.08.013. Epub 2014 Sep 17.
NCT00096083	No publish
NCT01640808	No publish
NCT00575523	No publish
NCT00059865	Alberts SR, Sande JR, Foster NR, Quevedo FJ, McWilliams RR, Kugler JW, Fitch TR, Jaslowski AJ. Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943. J Gastrointest Cancer. 2007;38(2-4):87-94. doi: 10.1007/s12029-008-9037-8. Epub 2008 Nov 21.
NCT02575339	No publish
NCT02044224	No publish
NCT01213030	No publish
NCT00441376	No publish
NCT00122876	No publish
NCT01525069	No publish
NCT00101036	No publish
NCT02016391	No publish
NCT01665937	No publish
NCT00143403	No publish
NCT00003296	No publish
NCT00003557	No publish
NCT00537121	No publish
NCT00659022	No publish
NCT00009893	Alberts SR, Al-Khatib H, Mahoney MR, Burgart L, Cera PJ, Flynn PJ, Finch TR, Levitt R, Windschitl HE, Knost JA, Tschetter LK. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer. 2005 Jan 1;103(1):111-8.
NCT00005938	No publish
NCT01502410	No publish
NCT01313377	No publish
NCT00363584	No publish
NCT00437424	No publish
NCT03159585	No publish
NCT00844883	No publish
NCT03316222	No publish
NCT02273362	No publish
NCT02650375	No publish
NCT03107416	No publish
NCT01835223	No publish
NCT00999843	No publish
NCT01819961	No publish
NCT01658878	No publish
NCT03572582	No publish
NCT01437007	No publish
NCT03203304	No publish
NCT00988195	No publish
NCT02081755	No publish
NCT02101593	No publish
NCT02069041	No publish
NCT01298284	No publish
NCT01936233	No publish
NCT01204177	No publish
NCT00920192	No publish
NCT01972503	No publish
NCT03439891	No publish
NCT00877071	No publish
NCT02576964	No publish
NCT03199274	No publish
NCT00999882	No publish
NCT00746317	No publish
NCT00073905	Koeberle D, Saletti P, Borner M, Gerber D, Dietrich D, Caspar CB, Mingrone W, Beretta K, Strasser F, Ruhstaller T, Mora O, Herrmann R; Swiss Group for Clinical Cancer Research. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2008 Aug 1;26(22):3702-8. doi: 10.1200/JCO.2008.16.5704.
NCT01564810	No publish
NCT00976170	No publish
NCT01540461	No publish
NCT01004978	No publish
NCT02968810	No publish
NCT01015833	No publish
NCT00906373	No publish
NCT03278925	No publish
NCT00980460	No publish
NCT00327652	No publish
NCT00094003	No publish
NCT00567216	No publish
NCT00003923	No publish
NCT01766219	No publish
NCT01217034	No publish
NCT02767375	Korean Liver Cancer Study Group (KLCSG); National Cancer Center, Korea (NCC). 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol. 2015 May-Jun;16(3):465-522. doi: 10.3348/kjr.2015.16.3.465. Epub 2015 May 13.
NCT01655641	Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med. 2007 May 31;356(22):2301-11. Review.
NCT00986661	No publish
NCT01171924	No publish
NCT01562821	Shao YF, Yang JM, Chau GY, Sirivatanauksorn Y, Zhong SX, Erhardtsen E, Nivatvongs S, Lee PH. Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Am J Surg. 2006 Feb;191(2):245-9.
NCT02528526	No publish
NCT01307878	No publish
NCT00486356	No publish
NCT01075399	No publish
NCT01423708	No publish
NCT02240433	No publish
NCT00872014	No publish
NCT00355238	No publish
NCT00553332	Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011 Jun 10;29(17):2357-63. doi: 10.1200/JCO.2010.33.9473. Epub 2011 Apr 25.
NCT00019630	No publish
NCT02842125	No publish
NCT01347424	No publish
NCT00661622	No publish
NCT01743469	No publish
NCT00021047	No publish
NCT00103298	No publish
NCT00089401	No publish
NCT00020501	No publish
NCT02174575	No publish
NCT03058289	No publish
NCT02435433	No publish
NCT01214343	No publish
NCT00712855	No publish
NCT00054951	No publish
NCT03419897	No publish
NCT03412773	No publish
NCT00019474	No publish
NCT00187109	No publish
NCT00987766	No publish
NCT02869217	No publish
NCT00107536	Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.
NCT01120288	No publish
NCT01394497	D'Amico F, Vitale A, Piovan D, Bertacco A, Ramirez Morales R, Chiara Frigo A, Bassi D, Bonsignore P, Gringeri E, Valmasoni M, Garbo G, Lodo E, D'Amico FE, Scopelliti M, Carraro A, Gambato M, Brolese A, Zanus G, Neri D, Cillo U. Use of N-acetylcysteine during liver procurement: a prospective randomized controlled study. Liver Transpl. 2013 Feb;19(2):135-44. doi: 10.1002/lt.23527. Epub 2012 Sep 26.
NCT01967823	No publish
NCT00033462	No publish
NCT03253289	No publish
NCT00516165	No publish
NCT00716976	No publish
NCT00654160	No publish
NCT01498952	No publish
NCT00024258	No publish
NCT00041808	No publish
NCT00007813	Leung W, Chen AR, Klann RC, Moss TJ, Davis JM, Noga SJ, Cohen KJ, Friedman AD, Small D, Schwartz CL, Borowitz MJ, Wharam MD, Paidas CN, Long CA, Karandish S, McMannis JD, Kastan MB, Civin CI. Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. Bone Marrow Transplant. 1998 Nov;22(10):971-9.
NCT00002515	No publish
NCT00036959	Fox E, Maris JM, Cohn SL, Goodspeed W, Goodwin A, Kromplewski M, Medina D, Xiong H, Krivoshik A, Widemann B, Adamson PC, Balis FM. Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors. Cancer Chemother Pharmacol. 2010 Sep;66(4):737-43. doi: 10.1007/s00280-009-1218-z. Epub 2010 Jan 1.
NCT02145559	No publish
NCT00003427	Kemeny N, Tong W, Gonen M, Stockman J, Di Lauro C, Teitcher J, White P, Price C, Saltz L, Sharma S, Graham MA. Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer. Ann Oncol. 2002 Sep;13(9):1490-6.
NCT00019331	No publish
NCT00019513	No publish
NCT01042691	No publish
NCT03347292	No publish
NCT02042443	No publish
NCT03199586	No publish
NCT00303940	Meany H, Balis FM, Aikin A, Whitcomb P, Murphy RF, Steinberg SM, Widemann BC, Fox E. Pediatric phase I trial design using maximum target inhibition as the primary endpoint. J Natl Cancer Inst. 2010 Jun 16;102(12):909-12. doi: 10.1093/jnci/djq174. Epub 2010 May 11.
NCT02431676	No publish
NCT02094625	No publish
NCT00105443	Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
NCT02662348	No publish
NCT00617981	No publish
NCT00020150	Meany HJ, Warren KE, Fox E, Cole DE, Aikin AA, Balis FM. Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors. Cancer Chemother Pharmacol. 2009 Dec;65(1):137-42. doi: 10.1007/s00280-009-1015-8. Epub 2009 May 9.
NCT00030108	Widemann BC, Goodspeed W, Goodwin A, Fojo T, Balis FM, Fox E. Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors. J Clin Oncol. 2009 Feb 1;27(4):550-6. doi: 10.1200/JCO.2008.17.6644. Epub 2008 Dec 15.
NCT00666978	No publish
NCT00273312	Zhou Q, Wong CH, Lau CP, Hui CW, Lui VW, Chan SL, Yeo W. Enhanced Antitumor Activity with Combining Effect of mTOR Inhibition and Microtubule Stabilization in Hepatocellular Carcinoma. Int J Hepatol. 2013;2013:103830. doi: 10.1155/2013/103830. Epub 2013 Feb 20.
NCT00534001	No publish
NCT00365508	No publish
NCT02529774	No publish
NCT02316028	No publish
NCT00031681	No publish
NCT00397384	No publish
NCT00030498	No publish
NCT01643499	No publish
NCT03329950	No publish
NCT00892424	No publish
NCT02557490	No publish
NCT02015169	No publish
NCT02380131	No publish
NCT00208260	No publish
NCT00608361	No publish
NCT01322178	No publish
NCT01763450	No publish
NCT00630045	No publish
NCT00501605	No publish
NCT00806663	No publish
NCT02082210	No publish
NCT01010126	No publish
NCT02465112	No publish
NCT02453490	No publish
NCT01425879	No publish
NCT03493048	No publish
NCT03493061	No publish
NCT01456078	No publish
NCT01511146	No publish
NCT01384994	No publish
NCT01186263	No publish
NCT01469572	No publish
NCT00707681	No publish
NCT00153998	No publish
NCT03500874	No publish
NCT02070549	No publish
NCT01858207	No publish
NCT01203787	No publish
NCT01959061	No publish
NCT00264446	No publish
NCT00044512	Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006 Sep 10;24(26):4293-300. Epub 2006 Aug 14.
NCT00557557	No publish
NCT00101270	No publish
NCT00091182	No publish
NCT00012181	No publish
NCT01442935	No publish
NCT00200200	No publish
NCT02947165	No publish
NCT01008917	No publish
NCT02086656	No publish
NCT03195699	No publish
NCT00790218	No publish
NCT01035385	No publish
NCT03053466	No publish
NCT01962376	No publish
NCT02754856	No publish
NCT01387295	No publish
NCT01260415	No publish
NCT00234182	No publish
NCT01387373	No publish
NCT02172651	No publish
NCT01348412	No publish
NCT00743678	No publish
NCT00997685	No publish
NCT03428477	No publish
NCT00852228	No publish
NCT02151864	No publish
NCT02006030	No publish
NCT01488487	No publish
NCT00866944	No publish
NCT00108953	Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006 Sep 10;24(26):4293-300. Epub 2006 Aug 14.
NCT00494299	Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, Yoon JH, Hori T, Kumada H, Hayashi N, Kaneko S, Tsubouchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Meinhardt G, Okita K. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 2011 Sep;47(14):2117-27. doi: 10.1016/j.ejca.2011.05.007.
NCT00156975	No publish
NCT01149304	Seidensticker M, Seidensticker R, Damm R, Mohnike K, Pech M, Sangro B, Hass P, Wust P, Kropf S, Gademann G, Ricke J. Prospective randomized trial of enoxaparin, pentoxifylline and ursodeoxycholic acid for prevention of radiation-induced liver toxicity. PLoS One. 2014 Nov 13;9(11):e112731. doi: 10.1371/journal.pone.0112731. eCollection 2014.
NCT03590119	No publish
NCT02727309	No publish
NCT00168155	No publish
NCT03582618	No publish
NCT02363049	No publish
NCT03326791	No publish
NCT01334112	No publish
NCT01777594	No publish
NCT01232296	No publish
NCT02988440	No publish
NCT00247728	No publish
NCT02939807	No publish
NCT02508467	No publish
NCT01171651	No publish
NCT01721941	No publish
NCT03366155	No publish
NCT02942329	No publish
NCT01869088	Vogl TJ, Trapp M, Schroeder H, Mack M, Schuster A, Schmitt J, Neuhaus P, Felix R. Transarterial chemoembolization for hepatocellular carcinoma: volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success-results from a liver transplantation center. Radiology. 2000 Feb;214(2):349-57.
NCT01102335	No publish
NCT03029988	No publish
NCT03299946	No publish
NCT00956436	No publish
NCT01908426	No publish
NCT03230318	No publish
NCT02018757	No publish
NCT01348256	No publish
NCT00692770	Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Berre MA, Meinhardt G, Llovet JM; STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015 Oct;16(13):1344-54. doi: 10.1016/S1470-2045(15)00198-9. Epub 2015 Sep 8.
NCT00827554	No publish
NCT00057395	No publish
NCT03008512	No publish
NCT02112656	No publish
NCT02959151	No publish
NCT01417546	No publish
NCT03291379	No publish
NCT03189992	No publish
NCT00538850	Rauck R, Reynolds L, Geach J, Bull J, Stearns L, Scherlis M, Parikh N, Dillaha L. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2012 May;28(5):859-70. doi: 10.1185/03007995.2012.683111. Epub 2012 May 2.
NCT00274885	No publish
NCT00016380	National Cancer Institute of Canada Clinical Trials Group (SC19), Wong RK, Paul N, Ding K, Whitehead M, Brundage M, Fyles A, Wilke D, Nabid A, Fortin A, Wilson D, McKenzie M, Ackerman I, Souhami L, Chabot P, Pater J. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). J Clin Oncol. 2006 Jul 20;24(21):3458-64.
NCT02204930	No publish
NCT00003867	Goel S, Jhawer M, Rajdev L, Hopkins U, Fehn K, Baker C, Chun HG, Makower D, Landau L, Hoffman A, Wadler S, Mani S. Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies. Am J Clin Oncol. 2002 Oct;25(5):528-34.
NCT02867592	No publish
NCT00019760	No publish
NCT03257761	No publish
NCT00005860	No publish
NCT00003548	No publish
NCT00720174	No publish
NCT00049296	Sanborn SL, Cooney MM, Dowlati A, Brell JM, Krishnamurthi S, Gibbons J, Bokar JA, Nock C, Ness A, Remick SC. Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles. Invest New Drugs. 2008 Aug;26(4):355-62. doi: 10.1007/s10637-008-9137-0. Epub 2008 May 10.
NCT00002854	No publish
NCT00250796	No publish
NCT02580253	No publish
NCT03592264	No publish
NCT03035006	No publish
NCT03439761	No publish
NCT03475953	No publish
NCT02423343	No publish
NCT02759601	No publish
NCT02102022	No publish
NCT02178722	No publish
NCT01631552	No publish
NCT02638857	No publish
NCT01752920	No publish
NCT01177397	No publish
NCT00073736	No publish
NCT00328770	No publish
NCT03563170	No publish
NCT03499626	No publish
NCT02115373	No publish
NCT01988493	No publish
NCT03203005	No publish
NCT03130712	No publish
NCT03084380	No publish
NCT03071094	No publish
NCT02859324	No publish
NCT02795429	No publish
NCT02772029	No publish
NCT02715362	No publish
NCT02650271	Ke Y, Ma L, You XM, Huang SX, Liang YR, Xiang BD, Li LQ, Zhong JH. Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy. Cancer Biol Med. 2013 Sep;10(3):158-64. doi: 10.7497/j.issn.2095-3941.2013.03.006.
NCT02642913	No publish
NCT02584556	No publish
NCT02560779	No publish
NCT02534337	No publish
NCT00005842	Schwartz G, Rowinsky EK, Rha SY, et al.: A phase I, pharmacokinetic, and biologic correlative study of R115777 and trastuzumab (herceptin) in patients with advanced cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-322, 2001.
NCT00010023	Chen TT, Ryan T, Potmesil M, et al.: Cisplatin/capecitabine: tolerance and activity in patients with upper gastrointestinal cancers. [Abstract] American Society of Clinical Oncology 2004 Gastrointestinal Cancers Symposium, 22-24 January 2004, San Francisco, CA. A-53, 2004.
NCT00020579	Ryan QC, Headlee D, Sparreboom A, et al.: A phase I trial of an oral histone deacetylase inhibitor, MS-275, in advanced solid tumor and lymphoma patients. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-802, 2003.
NCT00398814	Preliminary results / Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 26, No 15S (May 20 Supplement), 2008: 16024
NCT02400788	No publish
NCT02279719	No publish
NCT02240771	No publish
NCT01271504	No publish
NCT02645981	No publish
NCT02024087	No publish
NCT02013778	No publish
NCT01906216	No publish
NCT00768937	No publish
NCT01747642	No publish
NCT02229071	No publish
NCT00561522	No publish
NCT00882869	No publish
NCT01438450	No publish
NCT01406574	No publish
NCT02465060	No publish
NCT01116635	No publish
NCT00946153	No publish
NCT02129322	No publish
NCT03289533	No publish
NCT01251458	No publish
NCT00843934	No publish
NCT00784290	No publish
NCT00731445	No publish
NCT00933816	No publish
NCT00819650	No publish
NCT00820053	No publish
NCT03044587	No publish
NCT00155272	No publish
NCT03511222	No publish
NCT03515369	No publish
NCT03539822	No publish
NCT03507998	No publish
NCT00273247	No publish
NCT02527772	Lombardi G, Zustovich F, Farinati F, Cillo U, Vitale A, Zanus G, Donach M, Farina M, Zovato S, Pastorelli D. Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study. Cancer. 2011 Jan 1;117(1):125-33. doi: 10.1002/cncr.25578. Epub 2010 Aug 31.|Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, Yang TS, Bhudhisawasdi V, Kang WK, Zhou Y, Lee JH, Sun Y. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013 Oct 1;31(28):3501-8. doi: 10.1200/JCO.2012.44.5643. Epub 2013 Aug 26.
NCT03144661	No publish
NCT02423239	No publish
NCT03101488	No publish
NCT03222076	No publish
NCT02354898	No publish
NCT03319459	No publish
NCT02572687	No publish
NCT03095781	No publish
NCT02262455	No publish
NCT01546519	No publish
NCT03407001	No publish
NCT03009461	No publish
NCT03192644	No publish
NCT03219372	No publish
NCT03313596	No publish
NCT02387307	No publish
NCT02029690	No publish
NCT01174121	No publish
NCT02315066	No publish
NCT02755311	No publish
NCT03017326	No publish
NCT02232633	No publish
NCT02973516	No publish
NCT00849264	No publish
NCT03468231	No publish
NCT01953926	No publish
NCT02074202	No publish
NCT02650427	No publish
NCT00923481	No publish
NCT01522820	No publish
NCT01482442	No publish
NCT01575574	No publish
NCT01733004	No publish
NCT02586285	No publish
NCT00630084	No publish
NCT02452853	No publish
NCT00375245	No publish
NCT01272557	No publish
NCT02301091	No publish
NCT03591965	No publish
NCT03586973	No publish
NCT03578874	No publish
NCT01374750	No publish
NCT01533324	No publish
NCT03519997	No publish
NCT03516071	No publish
NCT03511703	No publish
NCT03510871	No publish
NCT03469479	No publish
NCT03447951	No publish
NCT03434379	No publish
NCT03433703	No publish
NCT03418922	No publish
NCT03407495	No publish
NCT03389126	No publish
NCT03382886	No publish
NCT03337841	No publish
NCT03303469	No publish
NCT03298451	No publish
NCT03268499	No publish
NCT03261791	No publish
NCT03245190	No publish
NCT03236649	No publish
NCT03236636	No publish
NCT03235167	No publish
NCT03212625	No publish
NCT03208335	No publish
NCT03192618	No publish
NCT03175705	No publish
NCT03175679	No publish
NCT03163992	No publish
NCT03145558	No publish
NCT00475956	No publish
NCT03114085	No publish
NCT03109886	No publish
NCT01839604	No publish
NCT03062358	No publish
NCT03059147	No publish
NCT01834963	No publish
NCT03048123	No publish
NCT03046979	No publish
NCT03024684	No publish
NCT03006926	No publish
NCT02987907	No publish
NCT00495846	Cebon J, Findlay M, Hargreaves C, Stockler M, Thompson P, Boyer M, Roberts S, Poon A, Scott AM, Kalff V, Garas G, Dowling A, Crawford D, Ring J, Basser R, Strickland A, Macdonald G, Green M, Nowak A, Dickman B, Dhillon H, Gebski V; Australasian Gastro-Intestinal Trials Group (AGITG) Ag0001H Investigators. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. Br J Cancer. 2006 Oct 9;95(7):853-61. Epub 2006 Sep 5. Erratum in: Br J Cancer. 2007 Apr 10;96(7):1154. Findlay, M [added]; Hargreaves, C [added]; Stockler, M [added]; Thompson, P [added]; Boyer, M [added]; Roberts, S [added]; Poon, A [added]; Scott, A M [added]; Kalff, V [added]; Garas, G [added]; Dowling, A [added]; Crawford, D [added]; Ring, J [added]; Ba.
NCT00390195	Shiah HS, Chen CY, Dai CY, Hsiao CF, Lin YJ, Su WC, Chang JY, Whang-Peng J, Lin PW, Huang JD, Chen LT. Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. Aliment Pharmacol Ther. 2013 Jan;37(1):62-73. doi: 10.1111/apt.12132. Epub 2012 Nov 8.|Treiber G. mTOR inhibitors for hepatocellular cancer: a forward-moving target. Expert Rev Anticancer Ther. 2009 Feb;9(2):247-61. doi: 10.1586/14737140.9.2.247. Review.
NCT00526617	Nuthalapati S, Munasinghe W, Giranda V, Xiong H. Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic Malignancies. Clin Pharmacokinet. 2018 Jan;57(1):51-58. doi: 10.1007/s40262-017-0547-z.
NCT02774187	Fan W, Zhang Y, Wang Y, Yao X, Yang J, Li J. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization. PLoS One. 2015 Mar 5;10(3):e0119312. doi: 10.1371/journal.pone.0119312. eCollection 2015.
NCT03518502	Cabrera R, Pannu DS, Caridi J, Firpi RJ, Soldevila-Pico C, Morelli G, Clark V, Suman A, George TJ Jr, Nelson DR. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2011 Jul;34(2):205-13. doi: 10.1111/j.1365-2036.2011.04697.x. Epub 2011 May 23.
NCT03116945	Gharib AM, Thomasson D, Li KC. Molecular imaging of hepatocellular carcinoma. Gastroenterology. 2004 Nov;127(5 Suppl 1):S153-8.
NCT02981498	He MK, Zou RH, Li QJ, Zhou ZG, Shen JX, Zhang YF, Yu ZS, Xu L, Shi M. Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis. Cardiovasc Intervent Radiol. 2018 May;41(5):734-743. doi: 10.1007/s00270-017-1874-z. Epub 2018 Jan 11.
NCT02973685	No publish
NCT02967887	No publish
NCT00168987	No publish
NCT02956772	No publish
NCT02953743	No publish
NCT02927626	No publish
NCT02905188	No publish
NCT02631499	No publish
NCT02867280	No publish
NCT02856126	No publish
NCT02834780	No publish
NCT02809534	No publish
NCT02799212	No publish
NCT03463876	No publish
NCT02562755	No publish
NCT02733809	No publish
NCT02716766	No publish
NCT03419481	No publish
NCT02702401	No publish
NCT02672488	No publish
NCT02658019	No publish
NCT01761266	No publish
NCT02630108	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5.
NCT03278444	No publish
NCT03275376	No publish
NCT02576509	No publish
NCT02564614	No publish
NCT02028949	No publish
NCT03551444	No publish
NCT02534961	No publish
NCT02528643	No publish
NCT02524119	No publish
NCT02509169	No publish
NCT02504983	Liang KH, Lin CL, Chen SF, Chiu CW, Yang PC, Chang ML, Lin CC, Sung KF, Yeh C, Hung CF, Chien RN, Yeh CT. GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Pharmacogenomics. 2016 Mar;17(4):353-66. doi: 10.2217/pgs.15.179. Epub 2016 Feb 12.
NCT02447679	No publish
NCT02436902	No publish
NCT02421185	No publish
NCT02418988	No publish
NCT02399033	No publish
NCT03007225	No publish
NCT02987699	Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002 May 18;359(9319):1734-9.
NCT02358395	No publish
NCT02971696	No publish
NCT02961998	No publish
NCT02338297	No publish
NCT02329860	No publish
NCT02308319	No publish
NCT02304289	No publish
NCT03253250	No publish
NCT02267213	No publish
NCT02253511	No publish
NCT01915589	No publish
NCT02311205	No publish
NCT02234986	No publish
NCT02210182	No publish
NCT01840592	No publish
NCT00846131	Kulik L, Vouche M, Koppe S, Lewandowski RJ, Mulcahy MF, Ganger D, Habib A, Karp J, Al-Saden P, Lacouture M, Cotliar J, Abecassis M, Baker T, Salem R. Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma. J Hepatol. 2014 Aug;61(2):309-17. doi: 10.1016/j.jhep.2014.03.023. Epub 2014 Mar 27.
NCT02178358	No publish
NCT02738697	Qin S, Cheng Y, Liang J, Shen L, Bai Y, Li J, Fan J, Liang L, Zhang Y, Wu G, Rau KM, Yang TS, Jian Z, Liang H, Sun Y. Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study. Oncologist. 2014 Nov;19(11):1169-78. doi: 10.1634/theoncologist.2014-0190. Epub 2014 Sep 15.
NCT01915602	No publish
NCT02724332	No publish
NCT02715492	No publish
NCT02128958	No publish
NCT01192971	No publish
NCT00355862	No publish
NCT01997957	No publish
NCT01972672	No publish
NCT01970748	No publish
NCT01966133	No publish
NCT01934829	Bosch FX, Ribes J, Cléries R, Díaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005 May;9(2):191-211, v. Review.
NCT02779465	Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J; Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004 Oct 7;351(15):1521-31.
NCT02771405	No publish
NCT01903694	No publish
NCT01897610	No publish
NCT01897038	No publish
NCT01894269	No publish
NCT01935700	No publish
NCT02426450	No publish
NCT00884520	No publish
NCT01774344	Finn RS, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Gerolami R, Caparello C, Cabrera R, Chang C, Sun W, LeBerre MA, Baumhauer A, Meinhardt G, Bruix J. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. J Hepatol. 2018 Aug;69(2):353-358. doi: 10.1016/j.jhep.2018.04.010. Epub 2018 Apr 26.
NCT02561546	No publish
NCT01755767	No publish
NCT01752933	No publish
NCT01737827	No publish
NCT01770431	No publish
NCT01715532	No publish
NCT01687673	No publish
NCT01681446	No publish
NCT01656265	No publish
NCT01655693	No publish
NCT01639703	No publish
NCT01605734	No publish
NCT01594125	No publish
NCT01567930	No publish
NCT02281266	No publish
NCT01507168	No publish
NCT01507064	No publish
NCT01377220	No publish
NCT01489566	No publish
NCT01451658	No publish
NCT01429961	No publish
NCT00080236	No publish
NCT01409499	No publish
NCT01381211	No publish
NCT01357486	No publish
NCT01806740	No publish
NCT01352728	No publish
NCT01308723	No publish
NCT01308645	No publish
NCT01287585	No publish
NCT01273662	No publish
NCT01258608	No publish
NCT01246986	No publish
NCT01170104	No publish
NCT01131689	No publish
NCT01129570	No publish
NCT01126463	No publish
NCT01098760	No publish
NCT01088581	No publish
NCT01055743	No publish
NCT01040559	No publish
NCT01035229	No publish
NCT01418729	No publish
NCT01004003	No publish
NCT01003015	Bruix J, Tak WY, Gasbarrini A, Santoro A, Colombo M, Lim HY, Mazzaferro V, Wiest R, Reig M, Wagner A, Bolondi L. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer. 2013 Nov;49(16):3412-9. doi: 10.1016/j.ejca.2013.05.028. Epub 2013 Jun 25.
NCT00990860	No publish
NCT00988741	No publish
NCT00987935	No publish
NCT00508001	No publish
NCT00149565	No publish
NCT01559844	No publish
NCT00943449	No publish
NCT00921531	No publish
NCT00908752	No publish
NCT00901901	No publish
NCT00892658	No publish
NCT01265576	No publish
NCT00858871	No publish
NCT00855218	No publish
NCT01259193	No publish
NCT00844688	No publish
NCT00829465	No publish
NCT00823290	No publish
NCT00805896	No publish
NCT00802555	No publish
NCT00752063	No publish
NCT00703365	No publish
NCT01263002	No publish
NCT00554125	No publish
NCT00635323	No publish
NCT00619541	No publish
NCT00559455	No publish
NCT00524498	No publish
NCT00519688	No publish
NCT00517920	No publish
NCT00492752	Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16.
NCT00490685	No publish
NCT00484211	Santoro A, Pressiani T, Citterio G, Rossoni G, Donadoni G, Pozzi F, Rimassa L, Personeni N, Bozzarelli S, Rossoni G, Colombi S, De Braud FG, Caligaris-Cappio F, Lambiase A, Bordignon C. Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. Br J Cancer. 2010 Sep 7;103(6):837-44. doi: 10.1038/sj.bjc.6605858. Epub 2010 Aug 17.
NCT00478374	Dufour JF, Hoppe H, Heim MH, Helbling B, Maurhofer O, Szucs-Farkas Z, Kickuth R, Borner M, Candinas D, Saar B. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist. 2010;15(11):1198-204. doi: 10.1634/theoncologist.2010-0180. Epub 2010 Oct 29.
NCT00834860	No publish
NCT00471965	No publish
NCT00464919	No publish
NCT00464295	No publish
NCT00460681	No publish
NCT00423306	No publish
NCT00960518	No publish
NCT00386984	Allgaier HP, Becker G, Blum HE. [A therapeutic study of hepatocellular carcinoma using octreotide (HECTOR). Hepatocellular Carcinoma: Treatment with Octreotide]. Dtsch Med Wochenschr. 2000 Mar 17;125(11):320. German.
NCT00384800	No publish
NCT00287222	No publish
NCT00768157	No publish
NCT00280618	No publish
NCT00241020	No publish
NCT00162669	No publish
NCT00142467	No publish
NCT00142428	No publish
NCT00082082	No publish
NCT00375661	No publish
NCT00056992	No publish
NCT00116454	No publish
NCT00043433	No publish
NCT00006332	No publish
NCT00003597	Angiolillo AL, Davenport V, Bonilla MA, van de Ven C, Ayello J, Militano O, Miller LL, Krailo M, Reaman G, Cairo MS; Children's Oncology Group. A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experience. Clin Cancer Res. 2005 Apr 1;11(7):2644-50.
NCT00073944	No publish
NCT02301104	No publish
NCT02162563	No publish
NCT00941655	Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, Webb CC, Walker M, Toomey MA, Schrump D, Pandalai P, Stojadinovic A, Avital I. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol. 2014 Sep;110(3):275-84. doi: 10.1002/jso.23633. Epub 2014 Jul 5.
NCT01453283	No publish
NCT01167049	No publish
NCT02693067	No publish
NCT01836653	No publish
NCT01632722	No publish
NCT03519074	No publish
NCT03398291	No publish
NCT00874406	No publish
NCT02912052	No publish
NCT00540982	No publish
NCT00408551	No publish
NCT00004142	No publish
NCT00438737	No publish
NCT01912222	No publish
NCT01070355	No publish
NCT02063529	No publish
NCT00508326	No publish
NCT01226719	No publish
NCT00742911	No publish
NCT01839877	No publish
NCT00803647	No publish
NCT00005077	No publish
NCT00507962	No publish
NCT00885885	No publish
NCT00882180	No publish
NCT02718430	No publish
NCT03340558	No publish
NCT00091117	No publish
NCT01695772	No publish
NCT00002793	No publish
NCT00006479	Benoist S, Nordlinger B. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases. Ann Surg Oncol. 2009 Sep;16(9):2385-90. doi: 10.1245/s10434-009-0492-7. Epub 2009 Jun 25. Review.
NCT02738606	No publish
NCT01022541	No publish
NCT02885753	No publish
NCT03403634	No publish
NCT00028626	No publish
NCT00002692	Current version of study NCT00002692 on ClinicalTrials.gov
NCT00482222	No publish
NCT02350530	No publish
NCT00049400	Current version of study NCT00049400 on ClinicalTrials.gov
NCT00513266	No publish
NCT00003834	Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005 Dec 20;23(36):9243-9. Epub 2005 Oct 17.
NCT03487939	No publish
NCT00023868	No publish
NCT03069950	No publish
NCT00006062	No publish
NCT00764595	No publish
NCT00002901	No publish
NCT02494973	No publish
NCT03401294	No publish
NCT00674024	No publish
NCT00006050	Ducreux M, Ychou M, Laplanche A, Gamelin E, Lasser P, Husseini F, Quenet F, Viret F, Jacob JH, Boige V, Elias D, Delperro JR, Luboinski M; gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2005 Aug 1;23(22):4881-7. Epub 2005 Jul 11.
NCT01802645	No publish
NCT00656123	No publish
NCT00544349	No publish
NCT00063960	No publish
NCT02634502	No publish
NCT00496509	No publish
NCT00002716	Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE 2nd, Zhang C, Mayer RJ. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006 Mar 20;24(9):1395-403. Epub 2006 Feb 27.
NCT00557102	No publish
NCT00003368	Venook AP, Enders Klein C, Fleming G, Hollis D, Leichman CG, Hohl R, Byrd J, Budman D, Villalona M, Marshall J, Rosner GL, Ramirez J, Kastrissios H, Ratain MJ. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol. 2003 Dec;14(12):1783-90.
NCT00008294	Kemeny N, Capanu M, D'Angelica M, Jarnagin W, Haviland D, Dematteo R, Fong Y. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol. 2009 Jul;20(7):1236-41. doi: 10.1093/annonc/mdn769. Epub 2009 Feb 20.
NCT03031444	Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.
NCT03164655	No publish
NCT00003753	No publish
NCT00492999	No publish
NCT00280410	No publish
NCT02102789	No publish
NCT00037804	No publish
NCT00002842	No publish
NCT00025415	No publish
NCT00026234	No publish
NCT01638533	No publish
NCT02559024	No publish
NCT00056030	No publish
NCT00030563	No publish
NCT00062348	Wittig A, Sheu-Grabellus SY, Collette L, Moss R, Brualla L, Sauerwein W. BPA uptake does not correlate with LAT1 and Ki67 expressions in tumor samples (results of EORTC trial 11001). Appl Radiat Isot. 2011 Dec;69(12):1807-12. doi: 10.1016/j.apradiso.2011.02.018. Epub 2011 Feb 16.
NCT00427310	O'Connell MJ, Lavery I, Yothers G, Paik S, Clark-Langone KM, Lopatin M, Watson D, Baehner FL, Shak S, Baker J, Cowens JW, Wolmark N. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol. 2010 Sep 1;28(25):3937-44. doi: 10.1200/JCO.2010.28.9538. Epub 2010 Aug 2.
NCT00537771	No publish
